Psychedelic Trials: New FDA Safety Guidelines
- A new framework aims to standardize how researchers report "set and setting" variables in clinical trials involving psychedelic drugs.
- The ReSPCT guidelines were developed using the Delphi method, incorporating input from 89 experts across 17 countries.
- Chloé Pronovost-Morgan, a psychiatry resident at McGill University and co-lead author, emphasized the importance of context.
New guidelines for psychedelic clinical trials are reshaping how researchers approach psychedelic studies. These new standards, developed wiht international expert input, aim to thoroughly document the “set and setting”—the patient’s mindset and environment during the experience—because they critically effect patient outcomes. The ReSPCT framework addresses inconsistencies in reporting that have previously stymied progress toward FDA approval of certain therapies. With a clear focus on complete trial reporting, this initiative, covered in News Directory 3, promises to improve the reliability and impact of future research. Discover what’s next for the evolving field of psychedelic-assisted therapy.
New Guidelines Standardize Reporting in Psychedelic Clinical Trials
Updated June 17, 2025
A new framework aims to standardize how researchers report “set and setting” variables in clinical trials involving psychedelic drugs. The guidelines, known as ReSPCT (Reporting of Setting in Psychedelic Clinical Trials), seek to account for a patient’s mental state and the surroundings during the psychedelic experience, factors known to significantly influence outcomes.
The ReSPCT guidelines were developed using the Delphi method, incorporating input from 89 experts across 17 countries. The panel included clinicians, researchers, and individuals with lived experience as clinical trial participants.The findings were published June 3 in Nature Medicine.
Dr. Chloé Pronovost-Morgan, a psychiatry resident at McGill University and co-lead author, emphasized the importance of context. She said the same psychedelic drug at the same dose can produce drastically different reactions based on the environment, ranging from severe anxiety to mystical experiences. A recent review revealed that most psychedelic trials lack detailed contextual information, hindering interpretation and replication of results.
The ReSPCT framework includes 30 variables across four key areas.Thes include the physical and sensory environment, such as the